4.6 Article

Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria

期刊

BRITISH JOURNAL OF ANAESTHESIA
卷 130, 期 5, 页码 611-621

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.bja.2022.12.013

关键词

cancer pain; central sensitisation; guidelines; neuropathic pain; nociceptive pain; nociplastic pain; oncology; precision medicine

向作者/读者索取更多资源

Pain after cancer is often underestimated and undertreated. Precision medicine offers a way to classify patients into different subgroups based on their individual characteristics and tailor treatment accordingly. The application of precision medicine to post-cancer pain is an emerging issue, particularly in identifying and treating nociplastic pain. The 2021 IASP clinical criteria provide a framework for classifying and treating nociplastic pain in cancer patients, and the CANPPHE Network aims to implement and improve this approach through a diagnostic manual and case illustrations.
Pain after cancer remains underestimated and undertreated. Precision medicine is a recent concept that refers to the ability to classify patients into subgroups that differ in their susceptibility to, biology, or prognosis of a particular disease, or in their response to a specific treatment, and thus to tailor treatment to the individual patient characteristics. Applying this to pain after cancer, the ability to classify post-cancer pain into the three major pain phenotypes (i.e. nociceptive, neuropathic, and nociplastic pain) and tailor pain treatment accordingly, is an emerging issue. This is especially relevant because available evidence suggests that nociplastic pain is present in an important subgroup of those patients experiencing post-cancer pain. The 2021 International Association for the Study of Pain (IASP) clinical criteria and grading system for nociplastic pain account for the need to identify and correctly classify patients according to the pain phenotype early in their treatment. These criteria are an important step towards precision pain medicine with great potential for the field of clinical oncology. Within this framework, the Cancer Pain Phenotyping (CANPPHE) Network, an international and interdisciplinary group of oncology clinicians and researchers from seven countries, applied the 2021 IASP clinical criteria for nociplastic pain to the growing population of those experiencing post-cancer pain. A manual is provided to allow clinicians to differentiate between predominant nociceptive, neuropathic, or nociplastic pain after cancer. A seven-step diagnostic approach is presented and illustrated using cases to enhance understanding and encourage effective implementation of this approach in clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据